Inhibitors of platelet signal transduction as anti-aggregatory drugs

Expert Opinion on Investigational Drugs
J Geiger

Abstract

In the treatment and prevention of cardiovascular diseases, inhibition of platelet aggregation is of fundamental importance. Inhibition of platelet aggregation can be achieved by either inhibition of membrane receptors or by interception of signalling pathways. While receptor antagonism provides high specificity, the inhibition of platelet signal transduction is more effective. The effectiveness results from the inhibition of platelets, regardless of the cause of activation. These common pathway inhibitors are either intercepting platelet activating mechanisms or amplifying the action of endogenous platelet inhibitors. The physiological anti-aggregants are the endothelial factors NO and prostacyclin, which elevate intracellular cGMP or cAMP content, respectively. By administration of NO-releasing agents, prostacyclin analogues or other cyclic nucleotide elevating drugs the platelet anti-aggregatory action of endothelial factors can be effectively mimicked. Besides antiplatelet activity these drugs also act on vascular smooth muscle causing relaxation and therefore vasodilation, an additional beneficial effect. Inhibition of phosphodiesterases causes elevation of platelet cyclic nucleotide content and thus inhibits platelet aggr...Continue Reading

References

Sep 12, 1979·Biochemical and Biophysical Research Communications·A M SieglM J Silver
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·G J RothP W Majerus
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Feb 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J GeigerU Walter
Nov 13, 1992·European Journal of Pharmacology·J F BrownB J Whittle
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J S StamlerJ Loscalzo
May 15, 1992·Thrombosis Research·T L YueG Feuerstein
Mar 1, 1992·General Pharmacology·J P de la CruzF Sanchez de la Cuesta
Jan 1, 1991·Advances in Experimental Medicine and Biology·D A BulloughK M Mullane
Apr 24, 1991·Biochimica Et Biophysica Acta·W L Smith, L J Marnett
Jan 1, 1990·Annual Review of Physiology·T J Rink, S O Sage
Jun 1, 1990·Journal of the Air & Waste Management Association·M G Johnston, W H Stevenson
Jan 1, 1987·European Journal of Clinical Pharmacology·W Krause, T Krais
Jan 1, 1989·Physiological Reviews·W Siess
Apr 15, 1989·The Biochemical Journal·W L Smith
Jan 1, 1985·Advances in Experimental Medicine and Biology·B J WhittleA C Rosam
Apr 1, 1987·British Journal of Pharmacology·B FurlongJ A Smith
May 14, 1987·The New England Journal of Medicine·G A FitzGerald
May 15, 1986·European Journal of Biochemistry·M HeckerS Terao
Jan 1, 1985·Medicinal Research Reviews·R C NickolsonH Vorbrüggen

❮ Previous
Next ❯

Citations

Nov 16, 2002·Prostaglandins & Other Lipid Mediators·Lee-Ho Wang, Richard J Kulmacz
Mar 17, 2009·Haematologica·José RiveraVicente Vicente
Sep 7, 2014·Naunyn-Schmiedeberg's Archives of Pharmacology·Sabine WolterRoland Seifert
Oct 9, 2014·International Journal of Molecular Sciences·Reinaldo Barros GeraldoHelena Carla Castro
Dec 10, 2014·Neurobiology of Learning and Memory·Josiane Woutheres BortolottoCarla Denise Bonan
Mar 18, 2008·Vascular Pharmacology·Subrata Chakrabarti, Jane E Freedman
Jan 20, 2009·Atherosclerosis·Jonathan M Gibbins
Jul 13, 2007·Immunological Reviews·Ana Kasirer-FriedeSanford J Shattil
Jun 3, 2008·British Journal of Pharmacology·M A D FerreiraA M Chudzinski-Tavassi
Feb 13, 2010·Journal of Thrombosis and Haemostasis : JTH·O DangelA Friebe
May 20, 2015·British Journal of Pharmacology·Sakthivel VaiyapuriJonathan M Gibbins
Jul 14, 2017·Canadian Journal of Physiology and Pharmacology·É CarrierP D'Orléans-Juste
Aug 20, 2014·Journal of the American Heart Association·Aaron L SverdlovJohn D Horowitz
Dec 1, 2007·Journal of Cardiovascular Pharmacology·Subrata ChakrabartiJane E Freedman
Jul 15, 2004·Journal of Cell Science·Jonathan M Gibbins

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.